An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis
Phase 2
Recruiting
- Conditions
- Systemic Sclerosis
- Registration Number
- JPRN-jRCT2031210481
- Lead Sponsor
- ishiura Tomoyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Diagnosis of Systemic Sclerosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria
-Systemic Sclerosis patients with moderate to sever skin sclerosis
Exclusion Criteria
-Patients witg a disease considered inappropriate for participation in clinical trials, such as serious cardiac / hepatic / renal / pulmonary / hematologic disease
-Patients with a diseases that could interfere with assessment of Systemic Scleorosis
-Patients with body weight less than 30.0kg
-Pregnant or lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method